TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06178900

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assisted by the AI-Gatekeeper software group
Description: The group will be received a AI-Gatekeeper software report on the probability of having coronary artery stenosis (≥50%) based on the routine test.
Study: NCT04868747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The participants receive perioperative lidocaine infusion with general anesthesia for gastrectomy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: The participants receive perioperative normal slaine infusion with general anesthesia for gastrectomy.
Study: NCT04740736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saline Infusion
Description: Patient with hypovolemia on day 1 will be randomized to a saline or sham infusion prior to the Day 2 exercise test.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Saline Infusion
Description: Patient with hypovolemia on day 1 will be randomized to a saline or sham infusion prior to the Day 2 exercise test.
Study: NCT06014580

Intervention type: OTHER
Intervention: Observational study
Description: This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
Study: NCT05456152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Tablet
Description: Sublingual zolpidem - 1 sublingual tablet 30 minutes before bed time.
Study: NCT05731232

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vivatlac Synbiotikum
Description: Each capsule of Vivatlac® Synbiotikum contains a total of 4.5 x 10˄9 colony forming units (CFU) of nine different probiotic bacteria. Probiotic bacteria strains and their CFU amount per capsule are: Lactococcus lactis Ll-23, 9.00 x 10˄8 CFU; Lactobacillus helveticus SP 27, 9.00 x 10˄8 CFU; Bifidobacterium longum Bl-05, 6.75 x 10˄8 CFU; Bifidobacterium breve Bb-03, 4.50 x 10˄8 CFU; Lacticaseibacillus rhamnosus Lr-32, 4.50 x 10˄8 CFU; Streptococcus thermophiles St-21, 4.50 x 10˄8 CFU; Lacticaseibacillus casei Lc-11, 2.25 x 10˄8 CFU; Lactiplantibacillus plantarum Lp-115, 2.25 x 10˄8 CFU; Bifidobacterium bifidum Bb-02, 2.25 x 10˄8 CFU. As a prebiotic component each capsule contains 63 mg of fructooligosaccharides.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vivatlac Synbiotikum
Description: Each capsule of Vivatlac® Synbiotikum contains a total of 4.5 x 10˄9 colony forming units (CFU) of nine different probiotic bacteria. Probiotic bacteria strains and their CFU amount per capsule are: Lactococcus lactis Ll-23, 9.00 x 10˄8 CFU; Lactobacillus helveticus SP 27, 9.00 x 10˄8 CFU; Bifidobacterium longum Bl-05, 6.75 x 10˄8 CFU; Bifidobacterium breve Bb-03, 4.50 x 10˄8 CFU; Lacticaseibacillus rhamnosus Lr-32, 4.50 x 10˄8 CFU; Streptococcus thermophiles St-21, 4.50 x 10˄8 CFU; Lacticaseibacillus casei Lc-11, 2.25 x 10˄8 CFU; Lactiplantibacillus plantarum Lp-115, 2.25 x 10˄8 CFU; Bifidobacterium bifidum Bb-02, 2.25 x 10˄8 CFU. As a prebiotic component each capsule contains 63 mg of fructooligosaccharides.
Study: NCT05847647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retrograde Filling Group
Description: Surgical curettage of the periapical lesion and root tip resection will be performed, MTA will be applied retrogradely and no material will be applied to the bone defect.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retrograde Filling+L-PRF Group
Description: 2. Group: Surgical curettage of the periapical lesion and root tip resection will be performed, MTA will be applied retrogradely and L-PRF will be applied to the bone defect (

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (Orthograde Filling Group / OG Group).
Description: 3. Group: Surgical curettage of the periapical lesion will be performed, MTA will be applied orthogradely without root tip resection and no material will be applied to the bone defect
Study: NCT06288022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: total tubeless mini-PCNL
Description: When finish the mini-PCNL operation, patient not receive placement both ureteral drainage tube (DJ-stent) and nephrostomy tube.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tubeless mini-PCNL
Description: When finish the mini-PCNL operation, patient receive placement ureteral drainage tube (DJ-stent) but not receive nephrostomy tube.
Study: NCT05884242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide (LPS)
Description: LPS will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide (LPS)
Description: LPS will be administered intravenously.
Study: NCT05160493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine and pregabalin
Description: S-ketamine and pregabalin~* Drug: Pregabalin • 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7),followed by dose reduction to 75mg once daily for 7days(POD8-14)~* Drug: S-ketamine infusion • 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline and placebo capsule
Description: Normal saline and placebo capsule
Study: NCT05548816

Intervention type: OTHER
Intervention: Handheld Dynamometer , Special tests and Modified DASH questionarre .
Description: A mix of tools , special tests and questionarre to help in confirming the diagnosis of subacromial impingement.
Study: NCT05379855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% atropine eye drops
Description: using 0.01% atropine eye drops for both eyes every night
Study: NCT05032638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist guided training
Description: Therapist guided period delivered virtually (WebEx/Zoom). Participants will be patients associated with NYULH and will have access to Zoom. Each session will last 45 min, and will completed 3x/week by research therapists, who are part of the study.
Study: NCT06145152

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adaptive exercise training
Description: The training recommendation for the day will be adjusted based on the readiness level. The adjustments can be both up or down (increased or decreased training)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Static exercise training
Description: The training recommendation for the day will not be adjusted based on the readiness level.
Study: NCT05716815

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT scans 2D Reconstruction
Description: Before performing the surgery, patient performs a chest CT scan with contrast medium and standard two-dimensional (2D) reconstructions are performed to study the lesion, the anatomy of the bronchi and the pulmonary venous and arterial vessels.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT scans 2D plus 3D Reconstruction
Description: Before performing the surgery, patient performs a chest CT scan with contrast medium and standard two-dimensional (2D) reconstructions plus a 3D reconstruction are performed to study the lesion, the anatomy of the bronchi and the pulmonary venous and arterial vessels.
Study: NCT05475574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of contact precautions for ESBLE
Description: Discontinuation of contact precaution : only standard precaution are implemented for any patient carrying (infected or colonized) ESBLE
Study: NCT05647018

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Percutaneous coronary angiography
Description: Percutaneous coronary intervention (PCI) refers to a family of minimally invasive procedures used to open clogged coronary arteries in patients presenting with myocardial infarction, through which installment of stents or intracoronary injection of drugs can take place.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Percutaneous coronary angiography
Description: Percutaneous coronary intervention (PCI) refers to a family of minimally invasive procedures used to open clogged coronary arteries in patients presenting with myocardial infarction, through which installment of stents or intracoronary injection of drugs can take place.
Study: NCT06190405

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hemoglobin A1c
Description: Patients with a HbA1c \<5.7% will be considered a normal test, and they will continue their routine prenatal care, including GDM screening at 24-28 weeks. Patients with a HbA1c ≥5.7% and ≤6.4% will be diagnosed with early GDM. Patients with a HbA1c ≥6.5% will be diagnosed with pregestational diabetes. Patient diagnosed with early GDM or pregestational diabetes will be treated as per usual clinical protocol for gestational/pregestational diabetes.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Risk-based screening by ACOG with two-step GTT
Description: Patients will be assessed for risk factors for GDM as per ACOG. Patients with a negative screen will continue routine care, including GDM screening at 24-28 weeks. Patients with a positive screen will undergo a two-step GTT screening. Patients with a 1-h GTT \<135 mg/dL will continue with routine care, including GDM screening at 24-28 weeks. Patients with a 1-h GTT ≥185 mg/dL and \<200 mg/dL will be diagnosed with early GDM. Patients with a 1-h GTT ≥200 mg/dL will be diagnosed with pregestational DM. Patients with a 1-h GTT ≥135 mg/dL and \<185 mg/dL will undergo a fasting 3-h GTT. Patient will be diagnosed with early GDM by Carpenter and Coustan criteria. Patients will be diagnosed with pregestational DM if their fasting glucose value is ≥126 mg/dL. If patients pass the 3-h GTT, they will continue routine care, including GDM screen at 24-28 weeks with a 3-h GTT. Patient diagnosed with early GDM/pregestational DM will be treated as per usual clinical protocol for GDM/pregestational DM.
Study: NCT05010525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-016
Description: 48 patients enrolled, orally, each 3 week (21-day) a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-016
Description: 48 patients enrolled, orally, each 3 week (21-day) a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-016
Description: 48 patients enrolled, orally, each 3 week (21-day) a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-016
Description: 48 patients enrolled, orally, each 3 week (21-day) a cycle
Study: NCT06410924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DD01
Description: Dual GLP-1 and glucagon receptor agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching DD01
Study: NCT05379855

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo eye drops (0.1% sodium hyaluronate ophthalmic solution)
Description: using placebo eye drops (0.1% sodium hyaluronate ophthalmic solution) for both eyes every night

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.05% atropine eye drops
Description: using 0.05% atropine eye drops for both eyes every night
Study: NCT05218382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: immersive virtual reality technology

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: No virtual reality
Description: Virtual reality with blank screen
Study: NCT05548816

Intervention type: OTHER
Intervention: Handheld Dynamometer , Special tests and Modified DASH questionarre .
Description: A mix of tools , special tests and questionarre to help in confirming the diagnosis of subacromial impingement.

Intervention type: OTHER
Intervention: Handheld Dynamometer , Special tests and Modified DASH questionarre .
Description: A mix of tools , special tests and questionarre to help in confirming the diagnosis of subacromial impingement.
Study: NCT05847647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (Orthograde Filling+L-PRF Group
Description: 4. Group: Surgical curettage of the periapical lesion will be performed, MTA will be applied orthogradely without root tip resection and L-PRF will be applied to the bone defect
Study: NCT05073939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Oxytocin
Description: Administration of oxytocin (24 international units) orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Administration of placebo orally
Study: NCT05200052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 mg Oral Tablet
Description: Colchicine loading dose 1 mg and maintenance dose 0.5 mg for 6 months in addition to standard anti ischemic treatment.
Study: NCT05092880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radioembolization
Description: holmium-166 microspheres

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care first-line systemic therapy
Description: Capecitabine plus anti-VEGF antibody
Study: NCT04857463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional supplement drink
Description: At the intervention period (0th to 12th week of the experiment), In addition to nutrition and health education, subjects were provided with 2 bottles of commercially available oral nutritional supplements (Meiji Mei Balance, Meiji Co., Ltd., Tokyo, Japan) every day, between lunch and dinner and before bedtime.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional education
Description: At the intervention period (0th to 12th week of the experiment) , subjects will be given regular nutrition education by a qualified clinical dietitian to ensure the effectiveness of nutrition education, in order for the nutrition education group to benefit from participating in this trial, the subjects will also be provided with the same nutritional products after the trial
Study: NCT06062849

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nephrostomy tube
Description: we will investigate if a nephrostomy tube really necessary after PNL operations

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: double J stent
Description: we will investigate if a JJ stent really necessary after PNL operations

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: totally tubless
Description: we will not insert any device after the procedure and investigate if a nephrostomy tube or JJ stent really necessary after PNL operations
Study: NCT06469489

Intervention type: OTHER
Intervention: Liver Disease of all etiologies
Description: No intervention
Study: NCT04979273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 40 % in Water
Description: injection of adrenaline 1:20.000, followed by dextrose 40% spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenaline 1 Mg/mL Solution for Injection
Description: injection of adrenaline 1:20.000, followed by thermocoagulation or hemoclip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenaline 1 Mg/mL Solution for Injection
Description: injection of adrenaline 1:20.000, followed by thermocoagulation or hemoclip

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: argon plasma coagulation
Description: Thermocoagulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemoclip
Description: Hemoclip
Study: NCT05389982

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mHealth (GetWell)
Description: GetWell Loop utilizes an interactive health care application to allow patients to more actively participate in their care. We plan to work with GetWell to develop a custom build plan for kidney stone formers to achieve key aspects of stone prevention and provide patient education. This care plan will be developed using native capabilities within GetWell Loop.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mHealth (GetWell)
Description: GetWell Loop utilizes an interactive health care application to allow patients to more actively participate in their care. We plan to work with GetWell to develop a custom build plan for kidney stone formers to achieve key aspects of stone prevention and provide patient education. This care plan will be developed using native capabilities within GetWell Loop.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: Office based pathway

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Office based pathway
Study: NCT05311917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home vision therapy
Description: a group of vision therapy procedures in home to improve convergence insufficiency

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: base in prism prescription
Description: base in prism prescription according to sheards criterion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: conventional placebo
Description: using near glasses with aimless eye training
Study: NCT05006872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIABE-TEXT
Description: Participants will receive 170 text messages in their mobile phones during twelve months.
Study: NCT04962984

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: blood sampling
Description: additional blood sampling for coagulation tests

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: additional blood sampling for coagulation tests

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: blood sampling
Description: additional blood sampling for coagulation tests
Study: NCT05534308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoperative taping
Description: The intervention group (IG) will be composed of patients undergoing phleboextraction with saphenectomy and intervention with contensive taping, on intraoperative period associated with compression with elastic stockings.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No trasoperative taping
Description: Patients will received only compression stockings after surgery
Study: NCT06236932

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: Hypocaloric Mediterranean Diet consist of a nutritional regimen with customized daily energy intake, calculated considering the Basal Metabolism and Physical Activity Level (LAF) of each patient. The distribution of macronutrients will be worked out as follows: ≃ 55-60% Carbohydrates (of which 80% are complex carbohydrates, pasta, bread, rice, whole grains and 20% simple sugars), ≃ 10-15% Proteins (of which the 60% of animal origin (meat, especially white) and 40% of vegetable origin (beans, chickpeas, lentils and legumes in general), ≃ 25-30% of lipids (predominantly olive oil).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: Hypocaloric Mediterranean Diet consist of a nutritional regimen with customized daily energy intake, calculated considering the Basal Metabolism and Physical Activity Level (LAF) of each patient. The distribution of macronutrients will be worked out as follows: ≃ 55-60% Carbohydrates (of which 80% are complex carbohydrates, pasta, bread, rice, whole grains and 20% simple sugars), ≃ 10-15% Proteins (of which the 60% of animal origin (meat, especially white) and 40% of vegetable origin (beans, chickpeas, lentils and legumes in general), ≃ 25-30% of lipids (predominantly olive oil).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin supplementation
Description: Melatonin (supplement formulation in capsules, 1mg/die one hour before sleep) will be associated with mediterranean diet for 12 w.
Study: NCT06271720

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: visceral manipulation
Description: visceral manipulation: A palpation technique will be applied till the barrier is felt and it will be applied until release is felt.~integrated neuromuscular inhibition: ischemic compression will be applied to trigger point of upper trapezius

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: integrated neuromuscular inhibition
Description: It involves applying direct sustained digital pressure to the TrP with sufficient force over dedicated time duration, to slow down the blood supply and relieve the tension within the involved muscle. The pressure is gradually applied, maintained and the gradually released
Study: NCT05931666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gong Mobilization
Description: Patients are treated with Gong mobilization protocol along with conventional therapy including ultrasound therapy, hot pack and conventional exercises consisting of codman exercises, ROM exercises and shoulder stabilization exercises.~Total of 3 sessions per week for 3 consecutive weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kaltenborn Mobilization
Description: Patients are treated with Kaltenborn mobilization protocol along with conventional therapy including ultrasound therapy, hot pack and conventional exercises consisting of codman exercises, ROM exercises and shoulder stabilization exercises.~Total of 3 sessions per week for 3 consecutive weeks.
Study: NCT05834166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper back strengthening and Postural correction
Description: The treatment protocol will involve upper back strengthening exercises and postural correction exercises 3 times a week for 10 to 15 minutes. Upper back strengthening will involve exercises with light-to-moderate load of free weights (body weight or resistance bands) or with a stability ball. Postural correction will involve maintaining the correct posture.
Study: NCT06215456

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality therapy
Description: VR therapy will be applied using a head mounted display, the PICO G2 4K headset (Barcelona, Spain). For VRD de application'SyncVR Relax \& Distract' (SyncVR Medical, Utrecht, The Netherlands) will be used. This application contains a wide range of relaxation games, relaxing 360 videos, and relaxation exercises each with a duration of 5-20 minutes. Patients can choose videos, games, or exercises according to their own preferences. For VRH sessions, the application HypnoVR (Strasbourg, France) will be used. This app contains several hypnotic narratives integrating sequences of controlled breathing, cardiac coherence, and hypnotic suggestions. Each VRH sessions can be personalized through selecting different environments and musical compositions.The first VRH session will be set to last 20 minutes and the second VRH session will be set to the continuous setting.